Blood stream infection (BSI) is a serious complication of hematopoietic stem cell transplantation (HSCT). The aim of this retrospective cohort analysis was to describe BSI after HSCT, and to assess the predictors and outcomes of BSI after HSCT using multivariable modeling. Of the 243 subjects transplanted, 56% received allogeneic HSCT and 106 (43.6%) developed BSI. Of the 185 isolates, 68% were Gram-positive cocci, 21% were Gram-negative bacilli (GNR) and 11% were fungi. Type of allogeneic HSCT was an independent risk factor for BSI (hazard ratio (HR) 3.26, 95% confidence interval (CI) 1.50, 7.07, P ¼ 0.01), as was the degree of HLA matching (HR 1.84, 95% CI 1.00, 3.37, P ¼ 0.05). BSI was a significant independent predictor of mortality after HSCT (HR 1.79, 95% CI 1.18, 2.73, P ¼ 0.007), after adjusting for acute graft-versus-host disease (GVHD) and allogeneic HSCT (both predicting death p3 months after HSCT). In contrast to the effects of acute GVHD and allogeneic HSCT, the effect of BSI was evident throughout the post-HSCT period. GNR BSI and vancomycin-resistant enterococcal BSI also were significantly associated with death. We concluded that BSI is a common complication of HSCT associated with increased mortality throughout the post-HSCT period.
Introduction
Blood stream infection (BSI) is the most common serious infectious complication of hematopoietic stem cell transplantation (HSCT). 1, 2 It has been observed to occur in 13-60% of HSCT recipients. 1, [3] [4] [5] [6] [7] [8] [9] [10] The differences in findings of these studies is likely due to factors such as different study designs, study populations, conditioning regimens and prophylactic antibiotic protocols. However, essentially all of the studies cited demonstrated that Gram-positive organisms, particularly coagulase-negative staphylococci and viridans group streptococci, were responsible for most BSI after HSCT. BSI usually occurs during the preengraftment phase but can occur more than 100 days after HSCT. 1, [10] [11] [12] [13] [14] Several risk factors for BSI after HSCT have been described. These include age greater than 18 years, underlying disease, late stage of underlying disease, the presence of a Hickman catheter infection, severe graft-versus-host disease (GVHD), mucositis and steroid use. 4, 10, [15] [16] [17] [18] [19] However, not all studies are in agreement.
The mortality associated with BSI in HSCT recipients is uncertain. In two studies, the crude mortality rates of HSCT recipients with BSI were 10-11% 12, 14 but in another, it was 27 versus 7% in those who did not develop BSI. 6 Other observers have demonstrated no difference in mortality between those HSCT recipients with and without BSI. 9, 16 Death associated with BSI was rare in several series of BSI in allogeneic HSCT recipients unless the offending organisms were Gram-negative bacilli (GNR). In this circumstance, the crude mortality rates were 24-40%. 1, 6, 19, 20 Thus, using crude mortality rates, there is little agreement in the literature regarding the impact of BSI on the mortality of HSCT recipients.
Although these studies provide much valuable data, their applicability to HSCT medicine in the current day is questionable since most focused on subjects who underwent transplantation in the early to mid-1990s. 15, 17, 18 Since then, there have been changes in the care of HSCT recipients, such as in conditioning regimens including reduced intensity regimens, and immunosuppression, and the occurrence of infections by resistant microorganisms, such as vancomycinresistant enterococci (VRE), as noted at our institution. 21 The current study was performed to describe the occurrence of BSI in a more recent cohort of HSCT recipients, to define risk factors and assess the outcomes of BSI, specifically mortality.
Patients and methods

Study subjects and design
This study was a retrospective cohort analysis of consecutive patients who underwent autologous, conventional allogeneic or reduced intensity allogeneic HSCT from June 1997 to December 2000. Records were reviewed for at least 6 months after HSCT unless death occurred before then. Subjects were derived from the Tufts-New England Medical Center HSCT Service's database that tracks over 600 recipients of HSCT since the inception of the program in 1992. Subjects received antimicrobial prophylaxis with a fluoroquinolone, antifungal prophylaxis with fluconazole and antiviral prophylaxis with acyclovir, all continuing until engraftment. After engraftment, patients received prophylaxis for Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole until 1 year after HSCT. Intravenous immunoglobulin was administered to patients undergoing allogeneic HSCT for the first seven months after HSCT. Initial acute GVHD prophylaxis in recipients of allogeneic HSCT consisted of cyclosporin and methotrexate, followed by cyclosporin alone. Cyclosporin was tapered off and replaced by mycophenolate mofetil that was continued for 1 year after HSCT unless GVHD developed. Central venous catheters present for the HSCT were generally removed after engraftment. Pre-specified clinical variables were abstracted in a standardized fashion from the medical record and the HSCT database. Data were entered into a database using StatView software (version 4.5, Abacus Concepts Inc., Berkely, CA, USA). This study was approved by the Tufts-New England Medical Center Institutional Review Board.
Definitions BSI was defined as the isolation of bacteria not normally known to colonize the skin, such as GNR, or certain pathogens such as Staphylococcus aureus or fungi, from at least one blood culture. 22 For bacteria that typically colonize the skin, such as coagulase-negative Staphylococcus, Propionibacterium, viridans group of Streptococcus and non-JK strains of Corynebacterium, two consecutive positive blood cultures, two positive blood cultures within 72 h, or one positive blood culture and one positive intravascular catheter tip culture within 72 h constituted a BSI. All blood cultures were obtained in response to an indication of infection, usually fever (oral temperature X381C). Reduced intensity HSCT refers to HSCT utilizing a novel conditioning regimen of pentostatin, extracorporeal photopheresis and reduced dose total body irradiation developed and in use at T-NEMC during the study period. 23 The criterion for engraftment was an absolute neutrophil count of 500/mm 3 or greater for three consecutive days. Acute GVHD was graded according to standard criteria. 24 For the purposes of this analysis, the maximum grade of acute GVHD that developed in each patient was used.
Statistics
Cox proportional hazards regression reporting hazard ratios (HR) and 95% confidence intervals (CI) were used in most univariate and all multivariable analyses. For the comparison between BSI before and after engraftment, logistic regression reporting odds ratios (OR) and 95% CI was used. Variables analyzed included demographic factors (age, gender), underlying disease necessitating HSCT, type of HSCT, time to engraftment and occurrence of acute GVHD as a categorical variable. Additionally, in the analysis of mortality, BSI (any, GNR BSI or VRE BSI compared with none) as a categorical variable was assessed. The assumption of proportional hazards was checked using Schoenfeld residuals and the %schoen and %daspline macros in SAS [25] [26] [27] or by testing for an interaction with time. 28 In instances where the proportional hazards assumption did not hold, time-dependent variables were created, as was the case when examining acute GVHD and type of HSCT as predictors of mortality in the multivariable models. Although acute GVHD and BSI occurred at various times after HSCT and therefore are timedependent variables, the exact date of onset of acute GVHD was not available. Therefore, both acute GVHD and BSI were expressed as categorical variables. When investigating the relationship between acute GVHD and degree of HLA matching as a predictor of either BSI or death, we adjusted for the type of HSCT (autologous versus allogeneic) in all analyses. This was performed to remove the type of HSCT as a confounder of effects thought due to acute GVHD or the degree of matching, since in autologous HSCT, matching and, in general, acute GVHD are not considered. For example, if acute GVHD was found to be a predictor of BSI in an unadjusted analysis of the entire cohort, the effect might have actually been due to the influence of autologous versus allogeneic HSCT, rather than due to acute GVHD versus no acute GVHD. For multivariable analyses, all variables with parameter estimates that had a P-value p0.15 in the univariate analysis were included. For the comparison between groups of medians of continuous variables, the Wilcoxon's rank sum test was used. In all analyses, a P-value of o0.05 was considered statistically significant.
Attributable mortality was calculated by the formula: (proportion dying in total cohort-proportion dying in group without BSI)/proportion dying in the total cohort Â 100%. 29 All analyses were performed using SAS (9.1, SAS, Cary, NC, USA). S-plus (6.2, Insightful Corp, Seattle, WA, USA) was used to create the graphs for the Kaplan-Meier survival analysis. Table 1 . One hundred and six (43%) patients experienced 159 episodes of BSI. Thirty-five percent of subjects with BSI had multiple episodes. The median time (interquartile range, IQR) to the first BSI was 15 days (6, 74 days) after HSCT. Sixty-three percent of subjects developing BSI did so within 30 days of HSCT ( Figure 1 ).
Results
Descriptive analysis
Microbiology
One hundred and eighty-five isolates were retrieved from the blood of the 106 subjects with BSI (Table 2 ). In 23 episodes (12%), more than one organism was isolated. Sixty-eight percent of isolates were Gram-positive cocci, the most common of which were coagulase-negative staphylococci (39.5% of total isolates). GNR accounted for 21.1% of all isolates. There were 21 fungal isolates (11.3%) retrieved from the blood of 17 subjects. All but two also had bacteremia during the course of the observation period.
Predictors of BSI
In a univariate analysis, lymphoma was associated with a reduced risk, and allogeneic HSCT was associated with an increased risk, of BSI (Table 1) . Age, gender, duration of neutropenia, receipt of TBI or acute GVHD status (controlled for allogeneic or autologous HSCT) was not associated with BSI. There was a trend toward an association between the degree of HLA mismatch between donor and recipient and BSI.
A multivariable model to determine independent risk factors for BSI was constructed using the variables age, underlying disease, degree of HLA matching between recipient and donor, and type of HSCT (Figure 2 ). Proportional hazards assumptions were met for these variables. In this model, reduced intensity allogeneic HSCT or a single HLA mismatch between the donor and recipient was independently associated with BSI.
To investigate if the risk factors for BSI before engraftment differed from those for BSI after engraftment, a subset analysis was performed directly comparing those with BSI before (n ¼ 58) and BSI after (n ¼ 48) engraftment. Using simple logistic regression, the following potential risk factors were assessed: age, gender, underlying disease, HSCT type, TBI and degree of HLA matching. There were no significant differences between the two groups although there was a trend for an increased risk of BSI before engraftment as opposed to after engraftment in those undergoing allogeneic HSCT compared with autologous HSCT (OR ¼ 2.08, 95% CI 0.89, 4.86; P ¼ 0.09).
Outcomes of BSI
The outcomes of length of stay of the HSCT admission and mortality after HSCT as associated with BSI were investigated. The median length of stay (IQR) of the initial HSCT admission in those subjects who did not develop BSI was 19.0 days (15.0, 25.0 days) and in subjects who did develop BSI, it was 25.5 days (18.0, 38.0 days; Po0.0001). Crude mortality rates were 50% in the BSI group and 30% in the subjects not experiencing BSI (Figure 3a) . The crude mortality rate in those experiencing GNR BSI and VRE BSI were 59 and 81%, respectively (Figure 3b and c) . The attributable risk of death due to BSI in the entire cohort was 22.6%.
In a univariate analysis, BSI, full-intensity allogeneic HSCT and acute GVHD grades 3-4, but not the time to engraftment, degree of HLA mismatch between donor and recipient or underlying disease, were risk factors for mortality (Table 3) .
In the multivariable analysis of mortality, the variables BSI, type of HSCT and acute GVHD were incorporated. It was determined that the variables type of HSCT and acute GVHD violated the proportional hazards assumption in that the hazard for time to death contributed by each variable changed at 3 months after HSCT. Therefore binary variables incorporating time-dependent methods and using a cut-off of 3 months were constructed and incorporated into the multivariable model (Figure 4 ). After adjusting for the two other variables, BSI was still an independent predictor of mortality. The hazard of death after HSCT contributed by BSI was significant throughout the post-HSCT period. The hazard of dying contributed independently by full-intensity allogeneic HSCT or acute GVHD grades 3-4 was significant only for the 3 month period immediately following HSCT (Figure 4) .
When adjusted for type of HSCT and acute GVHD, GNR BSI was associated with death compared to no BSI (HR 2.07, 95% CI 1.16, 3.69, P ¼ 0.02). In similar manner, VRE BSI compared to no BSI was also associated with death (HR 3.05, 95% CI 1.55, 5.99, P ¼ 0.001). The hazard of death contributed by each of these variables was significant during the entire post-HSCT period.
Discussion
This study confirms the common occurrence of BSI and the preponderance of Gram-positive cocci as blood isolates after HSCT. In addition, we have found that allogeneic HSCT and the degree of HLA mismatch between donor and recipient are independent risk factors for the development of BSI. As demonstrated by others, HSCT recipients are at high risk for infection compared to persons with lymphoma who have not undergone HSCT or with solid tumors. 30 The most common infection after HSCT is BSI, occurring in 13-60% of HSCT recipients. 1, [4] [5] [6] [7] [8] The source of most BSI is likely the skin, the oral mucosa or the gastrointestinal tract. 31 In the current study, the source of Figure 2 Multivariable analysis of predictors of BSI after HSCT.
BSI was not studied. However, it is likely that the skin was a common source in our population given the frequency of isolation of coagulase-negative staphylococci from the blood.
The common occurrence of BSI after HSCT is potentially due to numerous factors, such as the underlying disease and its treatment, resulting in prolonged and profound neutropenia, the disruption of protective barriers such as mucosal surfaces and the skin, immunosuppressive medication and GVHD. [32] [33] [34] However, our results do not suggest an effect of length of neutropenia, type of underlying disease or the occurrence of severe acute GVHD as factors associated with BSI. It is possible that the development of BSI before engraftment is associated with different risk factors than is BSI after engraftment as indicated by a trend for those persons undergoing allogeneic HSCT to develop BSI before rather than after engraftment. It is also possible that there are risk factors not analyzed in this analysis that differ in their influence on the development of BSI before as compared to after engraftment. Most BSI observed in this study occurred early (within the first 30 days) in the post-transplant course. However, it is important to note that BSI occurring late in the posttransplant course is not unusual, as demonstrated in this and other studies. 1, 10, [12] [13] [14] The independent risk factors for BSI of reduced intensity allogeneic HSCT and the degree of donor-recipient HLA mismatch determined in our study is not surprising. Possible explanations for this are the selection of more debilitated patients (and therefore at higher risk for BSI) for reduced intensity HSCT protocols and increased potential for the development of GVHD and the need for immunosuppressive medications if there is HLA mismatch between the donor and recipient. Since the time after HSCT that acute GVHD developed was not available, we could not determine whether or not there was a relationship between acute GVHD and subsequent BSI or, conversely, BSI and subsequent acute GVHD. This underscores the need for prospective studies that would incorporate predetermined clinical variables potentially important to the outcome of interest.
We have found that BSI is independently associated with increased mortality after HSCT. This finding has not been consistent in the literature. 9, 16 However, our observation is noted for all BSI, or BSI further categorized as due to GNR, BSI with organisms other than GNR or BSI with VRE. The contribution of BSI to mortality after HSCT is more striking when considering that (1) the observation remains even when adjusting for the presence of acute GVHD, a major cause of morbidity and mortality after HSCT and (2) the risk persisted throughout the entire post-HSCT period studied. This is in comparison to the other risk factors of acute GVHD and conventional allogeneic HSCT, whose contribution to an increased risk of death dissipates beyond 3 months after HSCT.
That there is an increased mortality in HSCT recipients associated with GNR BSI has been noted by others. 1, 6, 20 The large difference in mortality between those who had one or more episodes of VRE BSI and those who did not develop BSI is striking. The high mortality associated with VRE infection in neutropenic hosts has been noted by us and others (D Poutsiaka, in press). 21, 35, 36 One potential reason for our observed increased mortality in persons with VRE BSI is the lack of adequate therapy during the study period, since the introduction of quinupristin-dalfopristin, linezolid and daptomycin occurred either after or toward the end of the study period. However, it is also possible that, as in recipients of liver transplantation, VRE BSI is a marker for a debilitated host and not a direct contributor to death. Since BSI is a major complication of HSCT, it is likely that the prevention of BSI, particularly with GNR or VRE, will reduce morbidity and perhaps mortality in HSCT recipients. We and others have shown that antimicrobial prophylaxis is associated with reduced mortality after HSCT. 3 However, other strategies of preventing BSI after HSCT, such as reducing BSI from gut-derived pathogens like GNR or vancomycin-resistant Enterococcus, deserves further study.
There are several limitations to this study. Since it was retrospective in nature, certain data of interest were not available in the database, such as the time of onset of acute GVHD, and whether or not the initial antibiotic choices were appropriate, thereby limiting the analyses of risk factors of BSI and mortality. 1, 4, 6, 16, [38] [39] [40] [41] [42] [43] It is possible that the high proportion of coagulase-negative staphylococcal BSI was due to the consideration of contaminants in blood cultures as true bacteremias. However, in this study, such an influence of contaminants is less likely since (1) our definition of BSI with common skin contaminants was rigorous (at least two positive consecutive cultures or two positive cultures within 72 h of one another) and in accordance with that used by other investigators; 1, 4, 6, 16, [38] [39] [40] [41] [42] [43] (2) the cultures were obtained in response to an indication of infection as opposed to carried out for surveillance; and (3) the common isolation of coagulase-negative staphylococcal from the blood is consistent with other studies. 2, 6, 44, 45 It is more likely that the high proportion of coagulase-negative staphylococcal BSI was due to several factors including the presence of indwelling central venous catheters in virtually all of the patients in the early post-HSCT phase and the universal use of prophylaxis with fluoroquinolones. Finally, the group of patients undergoing reduced intensity HSCT was small, comprising 5% of the total cohort. Therefore, conclusions drawn regarding this group should be interpreted with caution and studies focusing on these patients should be undertaken. Figure 4 Multivariable analysis of predictors of death after HSCT.
